| Field | Specification |
|---|---|
| Target | |
| Alternative names | PTPRF, LAR, Leukocyte antigen related, Leukocyte antigen related PTP receptor, Leukocyte antigen related tyrosine phosphatase, Leukocyte common antigen related, Receptor-type tyrosine-protein phosphatase F, Receptor type tyrosine protein phosphatase F precursor, Protein Tyrosine Phosphatase Receptor Type F, Protein tyrosine phosphatase receptor type F polypeptide, Receptor linked phosphatase LAR, LAR protein, LARS, LARFN5C, LCA homolog, FLJ43335, FLJ45062, FLJ45567 |
| Accession number | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | Fusion protein amino acids 1315-1607 (cytoplasmic C-terminus) of human LAR. 97% identical in both rat and mouse. >80% identity with PTPRD and PTPRS. >50% identity with PTPRM and PTPRK. |
| Purification | |
| Cellular localization | |
| Concentration | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
LAR (Leukocyte Common Antigen-Related Protein), encoded by PTPRF, is a receptor-type protein tyrosine phosphatase involved in neural development and regeneration. It regulates cell adhesion, cytoskeletal dynamics, and synaptic plasticity by dephosphorylating β-catenin and modulating cadherin-mediated junctions. LAR influences neurite outgrowth, axon guidance, and actin remodeling, making it critical for neurodevelopment and repair. In neurodegenerative contexts, LAR dysregulation may impair synaptic stability and neuronal connectivity. Its role in insulin signaling and inflammation further links it to metabolic and neurodegenerative disorders. As a modulator of synaptic architecture and signaling, LAR represents a potential target for therapeutic strategies aimed at restoring neural function.
1 µg/ml of SMC-443 was sufficient for detection of LAR/PTPRF in 20 µg of rat brain lysate by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
Cite this product varies by variant:
- SMC-443D — Size: 100 ug: LAR Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-443D, RRID: AB_2701721)
- SMC-443D-A390 — Size: 100 ug: LAR Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-443D-A390, RRID: AB_2701722)
- SMC-443D-A488 — Size: 100 ug: LAR Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-443D-A488, RRID: AB_2701723)
- SMC-443D-A594 — Size: 100 ug: LAR Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-443D-A594, RRID: AB_2701725)
- SMC-443D-APC — Size: 100 ug: LAR Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-443D-APC, RRID: AB_2701731)
- SMC-443D-BI — Size: 100 ug: LAR Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-443D-BI, RRID: AB_2701732)
- SMC-443D-FITC — Size: 100 ug: LAR Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-443D-FITC, RRID: AB_2701733)
- SMC-443D-HRP — Size: 100 ug: LAR Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-443D-HRP, RRID: AB_2701734)
- SMC-443D-PCP — Size: 100 ug: LAR Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-443D-PCP, RRID: AB_2701736)
- SMC-443D-RPE — Size: 100 ug: LAR Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-443D-RPE, RRID: AB_2701737)
- SMC-443S — Size: 12 ug: LAR Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-443S, RRID: AB_2701721)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Mooney R.A. and C.M LeVea. (2003) Current Topics in Medicinal Chemistry, 3(7), 809-819.
3. Chagnon M.J., et al. (2004) Biochemistry and Cell Biology, 82(6), 664-675.
4. Ahmad F.F., and B.J. Goldstein (1997) Journal of Biological Chemistry, 272(1), 448-457.
